Publications
16th International Congress of Neuroimmunology (ISNI)
Sunday, August 20, 2023 – Thursday, August 24, 2023
Symposium 234: Mucosal Immunology – A Translational View into the Clinic
Thursday, July 6, 2023 – Saturday, July, 8, 2023
Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023
Wednesday, May 31, 2023 – Saturday, June 3, 2023
Digestive Disease Week 2023
Saturday, May 6, 2023 – Tuesday, May 9, 2023
8th European Congress of Virology 2023
Thursday, May 4, 2023 – Sunday, May 7, 2023
7th ISIRV-AVG Conference, Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19
Wednesday, May 3, 2023 – Friday, May 5, 2023
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications
Jan Vietor, Christian Gege, Tanja Stiller, Romy Busch, Espen Schallmayer, Hella Kohlhof, Georg Höfner, Jörg Pabel, Julian A. Marschner, and Daniel Merk*
Journal of Medicinal Chemistry
Published: April 26, 2023
https://doi.org/10.1021/acs.jmedchem.3c00415Annual Meeting of the Society for Virology
Tuesday, March 28, 2023 – Friday, March 31, 2023
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study
Thomas M. Polasek, Indika Leelasena, Irina Betscheider, Marija Marolt, Hella Kohlhof, Daniel Vitt, Frank Fliegert, Andreas R. Muehler
Clinical Pharmacology in Drug Development
Published: March 20, 2023ACTRIMS Forum 2023
POSTER PRESENTATION
Thursday, February 23, 2023 – Saturday, February 25, 2023
Immunic’s Celiac Disease R&D Webcast
Thursday, February 09, 2023
Outsourcing in Clinical Trials DACH 2022
Wednesday, November 30, 2022 – Thursday, December 1, 2022
Australasian Pharmaceutical Science Association (APSA) and Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) 2022 Joint Conference
Tuesday, November 29, 2022 – Friday, December 2, 2022
Immunic’s Multiple Sclerosis R&D Webcast
Thursday, November 17, 2022
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators
Jan Heering, Nathalie Jores, Whitney Kilu, Espen Schallmayer, Evelyn Peelen, Andreas Muehler, Hella Kohlhof, Daniel Vitt, Verena Linhard, Santosh L. Gande, Apirat Chaikuad, Sridhar Sreeramulu, Harald Schwalbe, Daniel Merk
ACS Chemical Biology
Published: November 1, 2022
https://doi.org/10.1021/acschembio.2c0059938th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, October 26, 2022 – Friday, October 28, 2022
19th International Celiac Disease Symposium (ICDS)
Wednesday, October 19, 2022 – Saturday, October 22, 2022
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Maria J. G. T. Vehreschild, Petar Atanasov, Kateryna Yurko, Cristian Oancea, Georgi Popov, Valentina Smesnoi, Gheorghe Placinta, Hella Kohlhof, Daniel Vitt, Evelyn Peelen, Jelena Mihajlović, Andreas R. Muehler
Infectious Diseases and Therapy
Published: October 15, 2022
https://doi.org/10.1007/s40121-022-00690-0IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects
Tuesday, September 20, 2022
B & T Cell-Mediated Autoimmune Disease Drug Development Summit
Tuesday, July 26, 2022 – Thursday, July 28, 2022
16th World Immune Regulation Meeting
Wednesday, July 6, 2022 – Saturday, July 9, 2022
A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis
Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler
Annals of Clinical and Translational Neurology
Published: June 14, 2022
https://doi.org/10.1002/acn3.5157413th International Congress on Autoimmunity
Friday, June 10, 2022 – Monday, June 13, 2022
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
Kim M. Stegmann et al.
iScience
Published: May 20, 2022
https://doi.org/10.1016/j.isci.2022.104293A Pilot Study of Vidofludimus Calcium for Treatment of Primary Sclerosing Cholangitis
Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor
Hepatology Communications
Published: March 3, 2022
https://doi.org/10.1002/hep4.192617th Congress of ECCO (European Crohn’s and Colitis Organization)
Wednesday, February 16, 2022 – Saturday, February 19, 2022
IMU-935: Phase 1 SAD/MAD Data in Healthy Human Subjects and Preclinical Update
Tuesday, December 14, 2021
37th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, October 13, 2021 – Friday, October 15, 2021
B&T Cell-Mediated Autoimmune Disease Drug Development Summit
Wednesday, October 6, 2021
50th Annual European Society for Dermatological Research (ESDR) Meeting
Wednesday, September 22, 2021 – Saturday, September 25, 2021
Virtual R&D Day: Update on the Preclinical and Clinical Development of IMU-935
Monday, July 12, 2021
The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021
Wednesday, June 30, 2021 – Saturday, July 3, 2021
IMU-838 in Multiple Sclerosis: Phase 3 Program in RRMS & Phase 2 Trial in PMS
Thursday, July 1, 2021
2021 Virtual AAN Annual Meeting
Saturday, April 17, 2021 – Thursday, April 22, 2021
30th Annual Meeting of the Society for Virology
Wednesday, March 24, 2021 – Friday, March 26, 2021
Main Phase 2 Analysis IMU-838 in Moderate COVID-19 & Phase 2 Proof-of-Concept Study IMU-838 in PSC
February 18, 2021
Clinical Relevance of Intestinal Barrier Dysfunction in Common Gastrointestinal Diseases
Andreas Muehler, Jason R. Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt
World Journal of Gastrointestinal Pathophysiology
Published: December 12, 2020
https://doi.org/10.4291/wjgp.v11.i6.114IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Brett Hurst, Justin Julander, Jonas Fuchs, Zsolt Ruzsics, Klaus Überla, Hans-Martin Jäck, Roger Ptak, Andreas Muehler, Manfred Gröppel, Daniel Vitt, Evelyn Peelen, Hella Kohlhof, Manfred Marschall
Viruses
Published: December 5, 2020
https://doi.org/10.3390/v12121394MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting
Friday, September 11, 2020 – Sunday, September 13, 2020
IMU-838 Phase 2 Data EMPhASIS Trial in RRMS
Monday, August 3, 2020
IMU-838 Phase 2 Top-Line Data EMPhASIS Trial in RRMS
Monday, August 3, 2020
Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity Against Mammarenaviruses In Vitro
Yu-Jin Kim, Beatrice Cubitt, Yingyun Cai, Jens H. Kuhn, Daniel Vitt, Hella Kohlhof, Juan C. de la Torre
Viruses
Published: July 29, 2020
https://doi.org/10.3390/v12080821Immunic’s Inaugural Virtual R&D Day
Tuesday, May 19, 2020
Vidofludimus Calcium, a Next Generation DHODH Inhibitor for the Treatment of Relapsing-Remitting Multiple Sclerosis
Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt
Multiple Sclerosis and Related Disorders
Published: May 6, 2020
https://doi.org/10.1016/j.msard.2020.102129Safety, Tolerability and Pharmacokinetics of Vidofludimus Calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
European Journal of Drug Metabolism and Pharmacokinetics
Published: May 2, 2020
https://doi.org/10.1007/s13318-020-00623-7Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)
Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Mühler
Neurology
Published: April 14, 2020IBD Innovate Conference: Product Development for Crohn’s and Colitis
Wednesday, December 4, 2019
New YorkUnited European Gastroenterology Week (UEGW)
Tuesday, October 22, 2019
Barcelona, SpainThe Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
Drugs in R&D
Published: October 16, 2019
https://doi.org/10.1007/s40268-019-00286-zCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019
Wednesday, September 11, 2019
Stockholm, SwedenGI Inflammatory Diseases Summit (GIIDS)
Monday, June 24, 2019
Boston
16th International Congress of Neuroimmunology (ISNI)
Sunday, August 20, 2023 – Thursday, August 24, 2023
Symposium 234: Mucosal Immunology – A Translational View into the Clinic
Thursday, July 6, 2023 – Saturday, July, 8, 2023
Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023
Wednesday, May 31, 2023 – Saturday, June 3, 2023
Digestive Disease Week 2023
Saturday, May 6, 2023 – Tuesday, May 9, 2023
8th European Congress of Virology 2023
Thursday, May 4, 2023 – Sunday, May 7, 2023
7th ISIRV-AVG Conference, Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19
Wednesday, May 3, 2023 – Friday, May 5, 2023
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications
Jan Vietor, Christian Gege, Tanja Stiller, Romy Busch, Espen Schallmayer, Hella Kohlhof, Georg Höfner, Jörg Pabel, Julian A. Marschner, and Daniel Merk*
Journal of Medicinal Chemistry
Published: April 26, 2023
https://doi.org/10.1021/acs.jmedchem.3c00415Annual Meeting of the Society for Virology
Tuesday, March 28, 2023 – Friday, March 31, 2023
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study
Thomas M. Polasek, Indika Leelasena, Irina Betscheider, Marija Marolt, Hella Kohlhof, Daniel Vitt, Frank Fliegert, Andreas R. Muehler
Clinical Pharmacology in Drug Development
Published: March 20, 2023ACTRIMS Forum 2023
POSTER PRESENTATION
Thursday, February 23, 2023 – Saturday, February 25, 2023
Immunic’s Celiac Disease R&D Webcast
Thursday, February 09, 2023
Outsourcing in Clinical Trials DACH 2022
Wednesday, November 30, 2022 – Thursday, December 1, 2022
Australasian Pharmaceutical Science Association (APSA) and Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) 2022 Joint Conference
Tuesday, November 29, 2022 – Friday, December 2, 2022
Immunic’s Multiple Sclerosis R&D Webcast
Thursday, November 17, 2022
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators
Jan Heering, Nathalie Jores, Whitney Kilu, Espen Schallmayer, Evelyn Peelen, Andreas Muehler, Hella Kohlhof, Daniel Vitt, Verena Linhard, Santosh L. Gande, Apirat Chaikuad, Sridhar Sreeramulu, Harald Schwalbe, Daniel Merk
ACS Chemical Biology
Published: November 1, 2022
https://doi.org/10.1021/acschembio.2c0059938th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, October 26, 2022 – Friday, October 28, 2022
19th International Celiac Disease Symposium (ICDS)
Wednesday, October 19, 2022 – Saturday, October 22, 2022
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Maria J. G. T. Vehreschild, Petar Atanasov, Kateryna Yurko, Cristian Oancea, Georgi Popov, Valentina Smesnoi, Gheorghe Placinta, Hella Kohlhof, Daniel Vitt, Evelyn Peelen, Jelena Mihajlović, Andreas R. Muehler
Infectious Diseases and Therapy
Published: October 15, 2022
https://doi.org/10.1007/s40121-022-00690-0IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects
Tuesday, September 20, 2022
B & T Cell-Mediated Autoimmune Disease Drug Development Summit
Tuesday, July 26, 2022 – Thursday, July 28, 2022
16th World Immune Regulation Meeting
Wednesday, July 6, 2022 – Saturday, July 9, 2022
A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis
Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler
Annals of Clinical and Translational Neurology
Published: June 14, 2022
https://doi.org/10.1002/acn3.5157413th International Congress on Autoimmunity
Friday, June 10, 2022 – Monday, June 13, 2022
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
Kim M. Stegmann et al.
iScience
Published: May 20, 2022
https://doi.org/10.1016/j.isci.2022.104293A Pilot Study of Vidofludimus Calcium for Treatment of Primary Sclerosing Cholangitis
Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor
Hepatology Communications
Published: March 3, 2022
https://doi.org/10.1002/hep4.192617th Congress of ECCO (European Crohn’s and Colitis Organization)
Wednesday, February 16, 2022 – Saturday, February 19, 2022
IMU-935: Phase 1 SAD/MAD Data in Healthy Human Subjects and Preclinical Update
Tuesday, December 14, 2021
37th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Wednesday, October 13, 2021 – Friday, October 15, 2021
B&T Cell-Mediated Autoimmune Disease Drug Development Summit
Wednesday, October 6, 2021
50th Annual European Society for Dermatological Research (ESDR) Meeting
Wednesday, September 22, 2021 – Saturday, September 25, 2021
Virtual R&D Day: Update on the Preclinical and Clinical Development of IMU-935
Monday, July 12, 2021
The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021
Wednesday, June 30, 2021 – Saturday, July 3, 2021
IMU-838 in Multiple Sclerosis: Phase 3 Program in RRMS & Phase 2 Trial in PMS
Thursday, July 1, 2021
2021 Virtual AAN Annual Meeting
Saturday, April 17, 2021 – Thursday, April 22, 2021
30th Annual Meeting of the Society for Virology
Wednesday, March 24, 2021 – Friday, March 26, 2021
Main Phase 2 Analysis IMU-838 in Moderate COVID-19 & Phase 2 Proof-of-Concept Study IMU-838 in PSC
February 18, 2021
Clinical Relevance of Intestinal Barrier Dysfunction in Common Gastrointestinal Diseases
Andreas Muehler, Jason R. Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt
World Journal of Gastrointestinal Pathophysiology
Published: December 12, 2020
https://doi.org/10.4291/wjgp.v11.i6.114IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Brett Hurst, Justin Julander, Jonas Fuchs, Zsolt Ruzsics, Klaus Überla, Hans-Martin Jäck, Roger Ptak, Andreas Muehler, Manfred Gröppel, Daniel Vitt, Evelyn Peelen, Hella Kohlhof, Manfred Marschall
Viruses
Published: December 5, 2020
https://doi.org/10.3390/v12121394MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting
Friday, September 11, 2020 – Sunday, September 13, 2020
IMU-838 Phase 2 Data EMPhASIS Trial in RRMS
Monday, August 3, 2020
IMU-838 Phase 2 Top-Line Data EMPhASIS Trial in RRMS
Monday, August 3, 2020
Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity Against Mammarenaviruses In Vitro
Yu-Jin Kim, Beatrice Cubitt, Yingyun Cai, Jens H. Kuhn, Daniel Vitt, Hella Kohlhof, Juan C. de la Torre
Viruses
Published: July 29, 2020
https://doi.org/10.3390/v12080821Immunic’s Inaugural Virtual R&D Day
Tuesday, May 19, 2020
Vidofludimus Calcium, a Next Generation DHODH Inhibitor for the Treatment of Relapsing-Remitting Multiple Sclerosis
Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt
Multiple Sclerosis and Related Disorders
Published: May 6, 2020
https://doi.org/10.1016/j.msard.2020.102129Safety, Tolerability and Pharmacokinetics of Vidofludimus Calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
European Journal of Drug Metabolism and Pharmacokinetics
Published: May 2, 2020
https://doi.org/10.1007/s13318-020-00623-7Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)
Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Mühler
Neurology
Published: April 14, 2020IBD Innovate Conference: Product Development for Crohn’s and Colitis
Wednesday, December 4, 2019
New YorkUnited European Gastroenterology Week (UEGW)
Tuesday, October 22, 2019
Barcelona, SpainThe Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
Drugs in R&D
Published: October 16, 2019
https://doi.org/10.1007/s40268-019-00286-zCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019
Wednesday, September 11, 2019
Stockholm, SwedenGI Inflammatory Diseases Summit (GIIDS)
Monday, June 24, 2019
Boston